Targacept announced the initiation of separate Phase 2 clinical studies of its product candidate TC-6987 for disorders characterized by inflammation—one in asthma and one in type 2 diabetes. Both studies are multicenter, double-blind, placebo-controlled, randomized parallel-group trials being conducted in the U.S. The primary efficacy outcome for the asthma trial is change in forced expiratory volume from baseline to end of dosing for patients receiving TC-6987 as compared with placebo. The primary efficacy outcome for the diabetes trial is change in fasting plasma glucose from baseline to end of dosing for patients receiving TC-6987 as compared to placebo.
TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor.
For more information call (336) 480-2100 or visit www.targacept.com.